Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 0.54 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.47 |
| ▸ | TAF1 | P21675 | 1/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167867 | 0.89 | MTOR (0.53) | ATRMTORKCNH2PIK3CAATRIP | |
| SCHEMBL4205311 | 0.89 | MTOR (0.53) | ATRMTORKCNH2PIK3CAATRIP | |
| SCHEMBL4207774 | 0.87 | ATR (0.47) | ATRMTORKCNH2PIK3CAATRIP | |
| SCHEMBL4168167 | 0.87 | ATR (0.47) | ATRMTORKCNH2PIK3CAATRIP | |
| SCHEMBL3936095 | 0.87 | ATR (0.63) | ATRMTORKCNH2PIK3CAATRIP | |
| SCHEMBL4200888 | 0.83 | ATR (0.59) | ATRMTORKCNH2PIK3CAATRIP | |
| SCHEMBL4207238 | 0.83 | ATR (0.59) | ATRMTORKCNH2PIK3CAATRIP | |
| SCHEMBL4202073 | 0.83 | ATR (0.59) | ATRMTORKCNH2PIK3CAATRIP | |
| SCHEMBL3927467 | 0.83 | PIK3CA (0.48) | ATRMTORKCNH2PIK3CAATRIP | |
| SCHEMBL3923841 | 0.81 | ATR (0.80) | ATRMTORPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| WO-2009007748-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018134-A1 | Compounds - 945 | MTOR, PIK3CA, PIK3R5 | ATR 1185/4885MTOR 1/4885KCNH2 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.